BEAUTY HEALTH CO/THE (SKIN) Stock Fundamental Analysis
USA - NASDAQ:SKIN - US88331L1089 - Common Stock
1.43 USD
+0.02 (+1.42%)
1.44 USD
+0.01 (+0.7%)
SKIN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 34 industry peers in the Personal Care Products industry. The financial health of SKIN is average, but there are quite some concerns on its profitability. SKIN has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year SKIN has reported negative net income.
In the past year SKIN had a positive cash flow from operations.
In the past 5 years SKIN reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: SKIN reported negative operating cash flow in multiple years.
1.2 Ratios
With a Return On Assets value of -3.74%, SKIN is not doing good in the industry: 64.71% of the companies in the same industry are doing better.
SKIN has a Return On Equity of -25.68%. This is in the lower half of the industry: SKIN underperforms 67.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.74% | ||
| ROE | -25.68% | ||
| ROIC | N/A |
ROA(3y)-3.53%
ROA(5y)-10.89%
ROE(3y)-66.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of SKIN (63.21%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of SKIN has declined.
The Profit Margin and Operating Margin are not available for SKIN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.21% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5YN/A
2. Health
2.1 Basic Checks
SKIN does not have a ROIC to compare to the WACC, probably because it is not profitable.
SKIN has more shares outstanding than it did 1 year ago.
The debt/assets ratio for SKIN is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -0.18, we must say that SKIN is in the distress zone and has some risk of bankruptcy.
SKIN has a worse Altman-Z score (-0.18) than 82.35% of its industry peers.
The Debt to FCF ratio of SKIN is 10.75, which is on the high side as it means it would take SKIN, 10.75 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 10.75, SKIN is doing good in the industry, outperforming 61.76% of the companies in the same industry.
SKIN has a Debt/Equity ratio of 4.91. This is a high value indicating a heavy dependency on external financing.
SKIN has a Debt to Equity ratio of 4.91. This is amonst the worse of the industry: SKIN underperforms 88.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.91 | ||
| Debt/FCF | 10.75 | ||
| Altman-Z | -0.18 |
ROIC/WACCN/A
WACC5.51%
2.3 Liquidity
SKIN has a Current Ratio of 5.15. This indicates that SKIN is financially healthy and has no problem in meeting its short term obligations.
SKIN has a Current ratio of 5.15. This is amongst the best in the industry. SKIN outperforms 94.12% of its industry peers.
SKIN has a Quick Ratio of 4.15. This indicates that SKIN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.15, SKIN belongs to the top of the industry, outperforming 94.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.15 | ||
| Quick Ratio | 4.15 |
3. Growth
3.1 Past
SKIN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1147.62%.
Looking at the last year, SKIN shows a very negative growth in Revenue. The Revenue has decreased by -15.33% in the last year.
Measured over the past years, SKIN shows a quite strong growth in Revenue. The Revenue has been growing by 8.72% on average per year.
EPS 1Y (TTM)-1147.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2900%
Revenue 1Y (TTM)-15.33%
Revenue growth 3Y8.73%
Revenue growth 5YN/A
Sales Q2Q%-13.69%
3.2 Future
SKIN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.76% yearly.
Based on estimates for the next years, SKIN will show a small growth in Revenue. The Revenue will grow by 2.41% on average per year.
EPS Next Y31.62%
EPS Next 2Y19.43%
EPS Next 3Y11.15%
EPS Next 5Y19.76%
Revenue Next Year-10.5%
Revenue Next 2Y-2.77%
Revenue Next 3Y-0.66%
Revenue Next 5Y2.41%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SKIN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SKIN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
SKIN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. SKIN is cheaper than 94.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.37 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.43%
EPS Next 3Y11.15%
5. Dividend
5.1 Amount
SKIN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.43
+0.02 (+1.42%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)
Earnings (Next)
Inst Owners85.29%
Inst Owner Change-0.55%
Ins Owners10.05%
Ins Owner Change12.12%
Market Cap181.37M
Revenue(TTM)310.06M
Net Income(TTM)-19005000
Analysts51.43
Price Target2.12 (48.25%)
Short Float %15.42%
Short Ratio18.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.76%
Min EPS beat(2)37.88%
Max EPS beat(2)155.64%
EPS beat(4)4
Avg EPS beat(4)60.34%
Min EPS beat(4)20.82%
Max EPS beat(4)155.64%
EPS beat(8)8
Avg EPS beat(8)57.58%
EPS beat(12)11
Avg EPS beat(12)64.71%
EPS beat(16)13
Avg EPS beat(16)-299.56%
Revenue beat(2)2
Avg Revenue beat(2)4.92%
Min Revenue beat(2)2.9%
Max Revenue beat(2)6.94%
Revenue beat(4)4
Avg Revenue beat(4)5.03%
Min Revenue beat(4)2.9%
Max Revenue beat(4)6.94%
Revenue beat(8)5
Avg Revenue beat(8)-0.02%
Revenue beat(12)7
Avg Revenue beat(12)0.21%
Revenue beat(16)11
Avg Revenue beat(16)3.62%
PT rev (1m)9.65%
PT rev (3m)18.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-18.31%
EPS NY rev (1m)0%
EPS NY rev (3m)45.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.58 | ||
| P/FCF | 5.37 | ||
| P/OCF | 4.6 | ||
| P/B | 2.45 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)0.27
FCFY18.62%
OCF(TTM)0.31
OCFY21.74%
SpS2.44
BVpS0.58
TBVpS-0.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.74% | ||
| ROE | -25.68% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.21% | ||
| FCFM | 10.89% |
ROA(3y)-3.53%
ROA(5y)-10.89%
ROE(3y)-66.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5YN/A
F-Score6
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.91 | ||
| Debt/FCF | 10.75 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 24.4% | ||
| Cap/Sales | 1.82% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.15 | ||
| Quick Ratio | 4.15 | ||
| Altman-Z | -0.18 |
F-Score6
WACC5.51%
ROIC/WACCN/A
Cap/Depr(3y)42.98%
Cap/Depr(5y)45.87%
Cap/Sales(3y)3.35%
Cap/Sales(5y)3.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1147.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2900%
EPS Next Y31.62%
EPS Next 2Y19.43%
EPS Next 3Y11.15%
EPS Next 5Y19.76%
Revenue 1Y (TTM)-15.33%
Revenue growth 3Y8.73%
Revenue growth 5YN/A
Sales Q2Q%-13.69%
Revenue Next Year-10.5%
Revenue Next 2Y-2.77%
Revenue Next 3Y-0.66%
Revenue Next 5Y2.41%
EBIT growth 1Y56.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year136.27%
EBIT Next 3Y34.01%
EBIT Next 5Y34.66%
FCF growth 1Y172.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y241.68%
OCF growth 3YN/A
OCF growth 5YN/A
BEAUTY HEALTH CO/THE / SKIN FAQ
Can you provide the ChartMill fundamental rating for BEAUTY HEALTH CO/THE?
ChartMill assigns a fundamental rating of 2 / 10 to SKIN.
Can you provide the valuation status for BEAUTY HEALTH CO/THE?
ChartMill assigns a valuation rating of 2 / 10 to BEAUTY HEALTH CO/THE (SKIN). This can be considered as Overvalued.
Can you provide the profitability details for BEAUTY HEALTH CO/THE?
BEAUTY HEALTH CO/THE (SKIN) has a profitability rating of 1 / 10.